cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.ftat3f
title: Occurrence Download

description: A dataset containing 7502 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Rubus anglocandicans"
 ]
}

 The dataset includes 7502 records from 38 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0000843-260108223611665/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30620804
title: Validation and Comparison of Live Microorganism Plating Analytical Procedures Following United States Pharmacopeia (USP) &lt;1220&gt; and &lt;1210&gt;

description: Properly validated procedures can reduce variation and lead to data that is more accurate and precise. Analytical procedure lifecycle management (APLM) is a statistical approach based on uncertainty measurements that validates procedures by demonstrating they are fit for purpose. APLM results can also be used to compare procedures. This paper builds upon previous publications that introduced, developed, and demonstrated the application of APLM as described in USP &lt;1220&gt; to a microbiological analytical procedure. The application of APLM is demonstrated in two MS EXCEL workbooks that are provided: <i>Template APLM</i>, that can be used to apply APLM to any microbiological plate count procedure and <i>Case Study APLM</i> detailing the APLM validation and comparison of enumeration procedures associated with a <i>Lactobacillus acidophilus</i> probiotic ingredient. The measurand and analytical target profile are clearly defined, a risk assessment is documented, and an analytical control strategy created. Two different procedures, ISO 20128 and USP &lt;64&gt;, are compared using tolerance intervals (TI) calculated from the procedures’ uncertainties. Tools to ease validation and comparison and all required statistical equations are contained within the workbooks. Case study data, which is based on a <i>Lactobacillus acidophilus</i>, single-strain, powdered ingredient, was generated in a manufacturing facility laboratory. This example of using APLM validated ISO 20128 as fit for the purpose of enumerating L. acidophilus in a powdered probiotic ingredient by showing that the intermediate precision (0.062 log<sub>10</sub> CFU/g) was less than the target measurement uncertainty (0.097 log<sub>10</sub> CFU/g). When comparing ISO 20128 to USP &lt;64&gt; overlapping tolerance intervals were observed; 11.14–11.76 log<sub>10</sub> CFU/g and 11.41 to 11.62 log<sub>10</sub> CFU/g, respectively. The results indicate the procedures are similar, but not equivalent. Options for using APLM and TI information are discussed. This study shows that APLM and tolerance intervals are useful tools that improve and ease procedure selection, assist in information gathering that leads to better understanding and control of analytical procedures, and helps improve data quality.
DOI: 10.6084/m9.figshare.30620804.v1
title: Validation and Comparison of Live Microorganism Plating Analytical Procedures Following United States Pharmacopeia (USP) &lt;1220&gt; and &lt;1210&gt;

description: Properly validated procedures can reduce variation and lead to data that is more accurate and precise. Analytical procedure lifecycle management (APLM) is a statistical approach based on uncertainty measurements that validates procedures by demonstrating they are fit for purpose. APLM results can also be used to compare procedures. This paper builds upon previous publications that introduced, developed, and demonstrated the application of APLM as described in USP &lt;1220&gt; to a microbiological analytical procedure. The application of APLM is demonstrated in two MS EXCEL workbooks that are provided: <i>Template APLM</i>, that can be used to apply APLM to any microbiological plate count procedure and <i>Case Study APLM</i> detailing the APLM validation and comparison of enumeration procedures associated with a <i>Lactobacillus acidophilus</i> probiotic ingredient. The measurand and analytical target profile are clearly defined, a risk assessment is documented, and an analytical control strategy created. Two different procedures, ISO 20128 and USP &lt;64&gt;, are compared using tolerance intervals (TI) calculated from the procedures’ uncertainties. Tools to ease validation and comparison and all required statistical equations are contained within the workbooks. Case study data, which is based on a <i>Lactobacillus acidophilus</i>, single-strain, powdered ingredient, was generated in a manufacturing facility laboratory. This example of using APLM validated ISO 20128 as fit for the purpose of enumerating L. acidophilus in a powdered probiotic ingredient by showing that the intermediate precision (0.062 log<sub>10</sub> CFU/g) was less than the target measurement uncertainty (0.097 log<sub>10</sub> CFU/g). When comparing ISO 20128 to USP &lt;64&gt; overlapping tolerance intervals were observed; 11.14–11.76 log<sub>10</sub> CFU/g and 11.41 to 11.62 log<sub>10</sub> CFU/g, respectively. The results indicate the procedures are similar, but not equivalent. Options for using APLM and TI information are discussed. This study shows that APLM and tolerance intervals are useful tools that improve and ease procedure selection, assist in information gathering that leads to better understanding and control of analytical procedures, and helps improve data quality.
DOI: 10.15156/bio/sh0156170.10fu
title: SH0156170.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.6084/m9.figshare.30675905
title: Nootropic Supplements and Exercise: Patterns and Perceptions of Cognitive Enhancer Use in Physically Active Individuals

description: ‘Nootropic’ describes compounds that enhance cognition. Dietary supplement companies leverage this concept as a descriptor for product marketing. Given that half of all American adults, as well as many active individuals, use a dietary supplement, the purpose of this study was to explore nootropic use in physically active individuals. Nootropic use was evaluated <i>via</i> an online survey. Preferred nootropics, dose, frequency, reasons for use, and perceived effects were evaluated. In total, 152 individuals (men <i>n</i> = 86, women <i>n</i> = 64, other <i>n</i> = 2; mean ± SD age = 27.42 ± 7.66) were eligible for analysis. Means, standard deviations, and percentages were determined, and chi-square (χ<sup>2</sup>) tests of independence were used to determine significant associations related to nootropic type, exercise characteristics, use tendencies, and perceived positive or negative effects (<i>p</i> &lt; 0.05). Thirty-six nootropics were reported, with caffeine (21.7%, <i>n</i> = 122), creatine (9.8%, <i>n</i> = 55), docosahexaenoic acid (DHA, Omega 3) (7.0%, <i>n</i> = 39), L-theanine and nicotine (both 6.6%, <i>n</i> = 37), and ashwagandha (6.1%, <i>n</i> = 34) the most frequently used. The most common reason for use was to increase energy and motivation (34.8%, <i>n</i> = 81). Those who predominantly engaged in weight training were more likely to use amino acids, peptides, and their derivatives (<i>p</i> &lt; 0.001). Those who use their respective nootropics more frequently perceived the nootropic to be more effective (<i>p</i> &lt; 0.001). This survey suggests that nootropic use is common in active individuals for diverse reasons that go beyond cognition enhancement.
DOI: 10.6084/m9.figshare.30675905.v1
title: Nootropic Supplements and Exercise: Patterns and Perceptions of Cognitive Enhancer Use in Physically Active Individuals

description: ‘Nootropic’ describes compounds that enhance cognition. Dietary supplement companies leverage this concept as a descriptor for product marketing. Given that half of all American adults, as well as many active individuals, use a dietary supplement, the purpose of this study was to explore nootropic use in physically active individuals. Nootropic use was evaluated <i>via</i> an online survey. Preferred nootropics, dose, frequency, reasons for use, and perceived effects were evaluated. In total, 152 individuals (men <i>n</i> = 86, women <i>n</i> = 64, other <i>n</i> = 2; mean ± SD age = 27.42 ± 7.66) were eligible for analysis. Means, standard deviations, and percentages were determined, and chi-square (χ<sup>2</sup>) tests of independence were used to determine significant associations related to nootropic type, exercise characteristics, use tendencies, and perceived positive or negative effects (<i>p</i> &lt; 0.05). Thirty-six nootropics were reported, with caffeine (21.7%, <i>n</i> = 122), creatine (9.8%, <i>n</i> = 55), docosahexaenoic acid (DHA, Omega 3) (7.0%, <i>n</i> = 39), L-theanine and nicotine (both 6.6%, <i>n</i> = 37), and ashwagandha (6.1%, <i>n</i> = 34) the most frequently used. The most common reason for use was to increase energy and motivation (34.8%, <i>n</i> = 81). Those who predominantly engaged in weight training were more likely to use amino acids, peptides, and their derivatives (<i>p</i> &lt; 0.001). Those who use their respective nootropics more frequently perceived the nootropic to be more effective (<i>p</i> &lt; 0.001). This survey suggests that nootropic use is common in active individuals for diverse reasons that go beyond cognition enhancement.
DOI: 10.15156/bio/sh0156171.10fu
title: SH0156171.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.6084/m9.figshare.30893800
title: Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial

description: Ischemic cardiomyopathy (ICM) is caused by oxidative stress, inflammation, and apoptosis. Alpha-lipoic acid (ALA) has antioxidant and anti-inflammatory effects. However, its effects on left ventricular dysfunction and myocardial fibrosis remain unclear. This study aims to investigate the effects of ALA on cardiac inflammation, fibrosis, and myocardial function as an adjuvant therapy for ICM. This double-blind, randomized, placebo-controlled, single-center trial enrolled 67 diabetic patients with ICM, who were randomized to receive either ALA 600 mg once daily or placebo for three months, in addition to ICM medications. Both groups were evaluated for tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), tissue growth factor-β1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and some echocardiographic indices before and after treatment. Sixty patients (aged 45–75 years; 70% males) completed the study (ALA group <i>n</i> = 30; placebo group <i>n</i> = 30). After three months, the ALA group exhibited significantly lower levels of TNF-α [443 (326/515) vs. 499 (448/657) pg/ml], CRP [4.5 (4.2/6.1) vs. 11 (6.3/12.1) mg/l], TGF-β1 [161 (104/189) vs. 206 (158/248) pg/ml], and MMP-2 [1450 (1164/1894) vs. 1815 (1339/2133) pg/ml] (<i>p</i> &lt; 0.05) compared to the placebo group. Furthermore, in the ALA group, there was a significant increase in LVEF [36% (34/40) vs. 28% (25/31.8)], whereas LVESD, LVEDD, and LAD were significantly decreased compared to the placebo group [4.7 (3.9/5.8) vs. 5.6 (5.1/5.6) cm; 6.1 ± 0.7 vs. 6.5 ± 0.5 cm; 4.2 (3.9/4.7) vs. 4.8 (4.4/5.1) cm] (<i>p</i> &lt; 0.05), respectively. Adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM. Additionally, our findings suggest that ALA may influence profibrotic signaling.
DOI: 10.6084/m9.figshare.30893800.v1
title: Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial

description: Ischemic cardiomyopathy (ICM) is caused by oxidative stress, inflammation, and apoptosis. Alpha-lipoic acid (ALA) has antioxidant and anti-inflammatory effects. However, its effects on left ventricular dysfunction and myocardial fibrosis remain unclear. This study aims to investigate the effects of ALA on cardiac inflammation, fibrosis, and myocardial function as an adjuvant therapy for ICM. This double-blind, randomized, placebo-controlled, single-center trial enrolled 67 diabetic patients with ICM, who were randomized to receive either ALA 600 mg once daily or placebo for three months, in addition to ICM medications. Both groups were evaluated for tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), tissue growth factor-β1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and some echocardiographic indices before and after treatment. Sixty patients (aged 45–75 years; 70% males) completed the study (ALA group <i>n</i> = 30; placebo group <i>n</i> = 30). After three months, the ALA group exhibited significantly lower levels of TNF-α [443 (326/515) vs. 499 (448/657) pg/ml], CRP [4.5 (4.2/6.1) vs. 11 (6.3/12.1) mg/l], TGF-β1 [161 (104/189) vs. 206 (158/248) pg/ml], and MMP-2 [1450 (1164/1894) vs. 1815 (1339/2133) pg/ml] (<i>p</i> &lt; 0.05) compared to the placebo group. Furthermore, in the ALA group, there was a significant increase in LVEF [36% (34/40) vs. 28% (25/31.8)], whereas LVESD, LVEDD, and LAD were significantly decreased compared to the placebo group [4.7 (3.9/5.8) vs. 5.6 (5.1/5.6) cm; 6.1 ± 0.7 vs. 6.5 ± 0.5 cm; 4.2 (3.9/4.7) vs. 4.8 (4.4/5.1) cm] (<i>p</i> &lt; 0.05), respectively. Adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM. Additionally, our findings suggest that ALA may influence profibrotic signaling.
DOI: 10.6084/m9.figshare.30957768
title: The Impact of Whey and Soy Protein Supplementation on Resistance Training in Young Adults: A Systematic Review and Meta-Analysis

description: Protein supplementation, particularly whey and soy protein, are widely used by individuals engaged in resistance exercise training (RET) to enhance lean body mass (LBM) and muscle strength. However, their effectiveness remain unclear due to conflicting study results. This systematic review and meta-analysis evaluated the effect of whey and soy protein supplementation on amino acid bioavailability, LBM, and strength performance in healthy young adults engaged in RET. Database searches were conducted in Cochrane, EBSCO Host, PubMed, and Scopus from inception to October 19, 2024 using a pre-defined search strategy. Initial screening resulted in a total of 1,813 studies that met the eligibility criteria. The inclusion criteria required participants to be trained or untrained young adults aged 18–30 years engaged in RET and taking either whey or soy protein in the form of concentrate or isolate with the primary outcome of LBM and secondary outcomes of bench press, squat, or plasma essential amino acid (EAA). The studies were assessed for risk of bias using the Cochrane RoB 2 tool, and a meta-analysis was conducted using a random-effects model. A total of 12 studies with 261 participants were included after full-text screening with the main reason for exclusion being wrong population. The analysis found no significant effect of either whey or soy protein supplementation on LBM. However, protein supplement increased peak plasma total EAA with whey protein significantly improved bench press (mean difference [MD] 8.87; 95% CI: 5.95–11.79) and squat performance (MD 9.60; 95% CI: 5.61–13.60), with low to no heterogeneity. These findings suggest whey protein supplementation can enhance strength without significantly altering LBM in young adults. However, further large-scale, high-quality randomized controlled trials are needed to establish definitive conclusions on the effects of protein supplementation RET. The review was registered August 30, 2024 in PROSPERO (CRD42024598070).
DOI: 10.6084/m9.figshare.30957768.v1
title: The Impact of Whey and Soy Protein Supplementation on Resistance Training in Young Adults: A Systematic Review and Meta-Analysis

description: Protein supplementation, particularly whey and soy protein, are widely used by individuals engaged in resistance exercise training (RET) to enhance lean body mass (LBM) and muscle strength. However, their effectiveness remain unclear due to conflicting study results. This systematic review and meta-analysis evaluated the effect of whey and soy protein supplementation on amino acid bioavailability, LBM, and strength performance in healthy young adults engaged in RET. Database searches were conducted in Cochrane, EBSCO Host, PubMed, and Scopus from inception to October 19, 2024 using a pre-defined search strategy. Initial screening resulted in a total of 1,813 studies that met the eligibility criteria. The inclusion criteria required participants to be trained or untrained young adults aged 18–30 years engaged in RET and taking either whey or soy protein in the form of concentrate or isolate with the primary outcome of LBM and secondary outcomes of bench press, squat, or plasma essential amino acid (EAA). The studies were assessed for risk of bias using the Cochrane RoB 2 tool, and a meta-analysis was conducted using a random-effects model. A total of 12 studies with 261 participants were included after full-text screening with the main reason for exclusion being wrong population. The analysis found no significant effect of either whey or soy protein supplementation on LBM. However, protein supplement increased peak plasma total EAA with whey protein significantly improved bench press (mean difference [MD] 8.87; 95% CI: 5.95–11.79) and squat performance (MD 9.60; 95% CI: 5.61–13.60), with low to no heterogeneity. These findings suggest whey protein supplementation can enhance strength without significantly altering LBM in young adults. However, further large-scale, high-quality randomized controlled trials are needed to establish definitive conclusions on the effects of protein supplementation RET. The review was registered August 30, 2024 in PROSPERO (CRD42024598070).
DOI: 10.15156/bio/sh0156172.10fu
title: SH0156172.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.15156/bio/sh0156173.10fu
title: SH0156173.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.6084/m9.figshare.30555558
title: Ginger (<i>Zingiber Officinale</i>) Supplementation and Biomarkers of Cardiovascular Disease – A Systematic Review

description: Ginger (<i>Zingiber officinale</i>) is one of the most widely used plant extracts and has been associated with improvements in biomarkers relevant to cardiovascular disease. Given the global burden of cardiovascular disease, this systematic review of randomized controlled trials aimed to evaluate the effects of ginger (<i>Zingiber officinale</i>) supplementation on biomarkers of cardiovascular disease. A systematic search of PubMed, Scopus, Web of Science Core Collection, and Google Scholar was performed up to January 2025 to identify eligible RCTs evaluating ginger supplementation. Outcomes included lipid profile, glycemic markers, blood pressure, inflammatory indicators, and liver enzymes. Data were pooled using weighted mean differences (WMDs). Subgroup and meta-regression analyses were conducted. Forty-one RCTs were included. Ginger supplementation was effective in improving FBS (WMD = −12.79 mg/dL; 95% CI = −18.57), insulin (WMD = −1.33 µIU/ml; 95% CI = −1.94, −0.71), HOMA-IR (WMD = −0.51; 95% CI = −0.68, −0.33), HbA1c (WMD = −0.68%; 95% CI = −1.00, −0.36), TG (WMD = −11.98 mg/dL; 95% CI = −23.27, −0.69), LDL (WMD = −4.55 mg/dL; 95% CI = −8.43, −0.68), HDL (WMD = 0.80 mg/dL; 95% CI = 0.01, 1.59), SBP (WMD = −2.72 mmHg; 95% CI = −5.25, −0.19), and ICAM-1 (WMD = −20.26 ng/ml; 95% CI = −40.49, −0.03). Ginger supplementation was not effective on the remaining outcomes. Ginger supplementation may improve several biomarkers of cardiovascular disease, with stronger effects in unhealthy individuals. Further studies are required to establish a clear cutoff for optimal dosage and intervention duration.